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Over the years, three-dimensional (3D) printing has gradually become more common in 
people's lives. Due to its quick development, it has attracted the attention of researchers in the 
pharmaceutical industry. The main purpose of this project was to couple fused deposition 
modelling (FDM) 3D printing with hot melt extrusion (HME) technology to manufacture tablets 
with different drug release profiles and to solve dose issues related to an individual’s 
physiological differences and to enhance extended release properties. Ketoprofen was used as the 
model drug and different properties were added to the polymer to create a formulation suited to 
HME technology for the production of filaments used for printing. 
This study also investigated polymer matrices and how 3D printing can affect a drug’s 
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The solid dispersion mainly means that the poorly soluble drug is dispersed in a water-
soluble carrier in an amorphous state. For poorly water soluble drugs, solid dispersions have 
been shown to significantly improve their dissolution rate, solubility and oral bioavailability. It 
improves the wettability of the drug by minimizing the particle size, thereby improving the oral 
bioavailability. In this study solid dispersion was obtained through a method called Hot Melt 
Extrusion (HME) (Vasconcelos, Sarmento and Costa, 2007; Sareen, Joseph and Mathew, 2012). 
HME has been used in the manufacturing process of the plastics industry for a long time, but 
only recently has it begun to show great potential in pharmaceutical use. When using the HME 
process for the creation of a pharmaceutical dosage, a homogeneous mixture of active 
pharmaceutical ingredient (API) and other excipients are rapidly heated and softened in the 
extruder and then pressurized into filaments through the die. In addition to improving the oral 
bioavailability of API, HME can also be used to develop controlled release drug systems and the 
ability to mask API’s bitter taste (Tiwari et al., 2016). HME is an effective technique for 
producing solid dispersions, which has great advantages over conventional processes for the high 
lipophilicity and poor solubility drugs. The use of HME technology to improve apparent 




technology as an important drug delivery processing tool (Repka et al., 2007). In recent years, 
more and more researchers have attempted to combine HME with 3D printing, and their 
achievements have also proved that this novel technology has great potential for development 
(Goyanes et al., 2015). 
In the traditional sense, three-dimensional printing(3DP) has changed the ink from the normal 
printer to thermoplastics. Now the most common 3D printing material is Polylactic Acid (PLA). 
PLA is an extremely common synthetic plastic with a low melting point and can be melt processed 
at 180°C. There are many factors that affect the use of filaments and 3D printing, but the most 
important parameters for evaluating whether a filament suits the production standards of a 3d 
printed medicine are the viscosity, stiffness and brittleness of the filament. These aspects are 
important during the printing process as filaments with the wrong attributes will often crack or 
detach from the 3d printer’s baseplate in such a way that printing cannot be completed. Since most 
of the plastics manufacturing industry typically uses PLA in 3d printing, we can use PLA as a 
reference to evaluate whether or not our extruded filaments meet the industry standard (Zhang et 
al., 2017). 
The principle of the fused deposition modelling (FDM) 3D printer is based on a digital model 
file, using an adhesive material such as plastic to construct an object by layer-by-layer printing. 
Until this layer is completely printed and cured that the next layer can be started. This covering 
surface and the curing process are repeated until the object is finished. The first step of 3D printing 




Fusion 360™) and then convert it to a STL file (Standard Mosaic Language or STereo-lithography) 
(Gross et al., 2014). 3d printers have a chamber dedicated to feeding a solid filament into the 
extruder; and while it is best to be able to feed continuously, the material can also be fed as a liquid 
using a pump. The material should uniform in its preparation so that the chemicals are distributed 
evenly in the final tablet form (Gibson et al., 2015). Once in the feeding chamber, the filament is 
then heated up to a melting point in a 3D printer which is then pushed through the extruder and 
printed as the design designated by the STL file. (Fig. 1). 
 
Figure 1. HME combined with 3D Printing process schematic diagram 
Under the Biopharmaceutical Classification System (BCS), drugs that have unit does that 
result in low solubility in 250ml of aqueous over a range of pH are classified as Class Ⅱ or Class 




absorption of BCS Class II and Class Ⅳ drugs (Sareen et al., 2012). According to the existing 
guidelines, ketoprofen is a weak acid, belonging to the BCS Class Ⅱ. Because of this, we needed 
to improve the solubility of Ketoprofen. 
3D printing has many advantages over traditional dosage forms so more manufacturers are 
investing in research and development. The first 3D printed prescription drug has already been 
successfully marketed in the US. Called Spritam-Aprecia, it was approved by the FDA in 2015 
for the treatment of partial epileptic seizures. This new dosage form requires only a little bit 
water to allow the tablet to dissolve quickly in the mouth, which also gives people who have 
difficulty swallowing more choices (Aprecia Pharmaceuticals, Langhorne, PA, USA). 
The gastrointestinal tract is the main limiting factor when looking at the speed of oral 
controlled release formulations. And while it is difficult to optimize the formulation to deal with 
this factor, it can be done through the control the dissolution process and by guiding the 
development and quality of the final product by studying the rate of release of in vitro controlled 
release formulations and predicting the rate of release through mathematical models. Drug 
dissolution is a complex process and while it is difficult to use a fixed mathematical model for all 
the dissolution data, it is possible. Current researchers tend to use some classical mathematical 
model to forecast the release for example, zero-order kinetic release model, first-order kinetic 
release model, Higuchi model and Ritger - Peppas model. These classic mathematical models are 




In this research, the intent is to investigate the different types of pharmaceutical polymers to 
prepare filaments suitable for 3D printing. The main objectives of this study are as follows: 1) 
Using Autodesk® Fusion 360™  to design an original model of the tablet for print. 2) Based on 
the physical and chemical properties of the API and polymer, select the appropriate polymers 
suitable for 3d printing. 3) Couple HME and FDM 3D Printing to print controlled release tablets 
of different densities. 4) Studying the in vivo dissolution release profile of 3D printed tablets. 
With the continuous development of the pharmaceutical field, the development of 
personalized doses of drugs has received increasing attention. 3D printing technology can meet 
the individual needs of people just as compared with traditional pharmaceutical dosage forms 












2. Materials and Methods 
2.1 Materials 
Ketoprofen (LGM Pharma, Jersey City, NJ, USA), the chemical used as the model API in 
this study, is an arylalkanoic acid compound. It has analgesic, anti-inflammatory and antipyretic 
effects, as well as a melting point of around 93-96 ° C. Other chemicals were also studied 
alongside the Ketoprofen. These include BenecelTM Hydroxypropyl methylcellulose(HPMC) 
K4M, AquaSolveTM Hydroxypropyl methylcellulose (HPMC) -AS HG, and KlucelTM 
hydroxypropylcellulose (HPC) LF wich were all donated by Ashland Inc. which is located in 
Covington, KY, US. 
a) Methods 
2.2.1 Formulations 
We created a filament made up of 30% (w/w) Ketoprofen, 50% (w/w) HPMC K4M and 
20% (w/w) HPMC- AS HG; we also made another filament with 30% (w/w) Ketoprofen, 50% 
(w/w) HPMC K4M and 10% (w/w) HPMC- AS HG 10% HPC LF. Both types of filament were 
prepared using a Thermo Fisher Scientific 11 twin-screw co-rotating extruder. Two formulations 


















F1 150 30 50 20 0 
F2 150 30 50 10 10 
 
2.2.2 HME Process 
The two formulations were mixed as a powder to ensure an even distribution of chemicals 
before we applied the HME process. Then a Thermo Scientific™ Pharma 11-mm diameter Twin-
screw Extruder (Thermo Fisher, Waltham, MA, US) was used in this study to prepare the 
filaments for printing. The formulations were extruded at 150℃ and the screw speed of 50 rpm 
in all zones with the standard configuration (Fig. 2). In addition, compared to the standard 3D 
Printing filament PLA and the 1.75mm diameter required of the 3D Printer; a 1.5mm round 






Figure 2. Standard screw configuration of Thermo Scientific™ Pharma 11-mm diameter Twin-screw Extruder. 
 
2.2.3 Filaments Texture Analysis 
A TA-XT2i analyzer (Texture Technologies, Hamilton, MA, USA) was used to test the 
filament stiffness in this study. Smooth and even filaments were selected for texture analysis and 
each segment was cut 5cm long. In order to better optimize the formulation, we performed a 
stiffness test and 3-point bend test. When performing stiffness tests, we set the conditions to a 
speed of 2 mm/s and a trigger force of 5.0 g. For the 3-point bending test, we easily found the 
breaking force, breaking distance, stiffness and other parameters for each filament. Each of the 
filaments was placed on a test bench with a size of 25 mm. The test speed was 10 mm/s with a 
trigger force of 5.0 g; this was done at distances of 10.00 mm. Fifteen filaments for each 
formulation were tested and data collection and analysis were performed using Exponent 





Figure 3. PLA 3-point bending test 
 
2.2.4 Model Design for 3D Printing 
Autodesk® Fusion 360TM (Autodesk Inc., USA) was used to design the tablet model we 
used in this study. The geometry of the selected dosage form is a tablet consisting of a cylindrical 
housing with a similarly shaped core (Figure 4). It was then exported as an STL file to be used 






Figure 4. 3D printing design of shell 
2.2.5 Thermogravimetric Analysis (TGA) 
Thermogravimetric analysis (TGA) is a thermal analysis method that measures the mass of a 
sample as its temperature changes over time. For this study, the samples were tested by using a 
PerkinElmer Pyris 1 TGA Thermogravimetric Analyzer (PerkinElmer Inc, Waltham, MA, USA). 
By heated the samples from room temperature to 350 ℃ at 10℃/min in an open aluminum pan 
and applied ultra-purified nitrogen as a purge gas at a rate of 35 ml /min, data was collected then 
analyzed using Pyris software (TA Instruments, LLC, Water, USA). 
 
2.2.6 Differential Scanning Calorimetry (DSC) 
Differential scanning calorimetry (DSC) is a thermal analysis technique. It can measure a 
variety of thermodynamic parameters. The mixing powder, filaments, and printed tablets were all 




measure and analyze the sample by heating the temperature from 10° C to 200 ° C at 25 ° C / 
min with a 5-15 mg sample inside a Tzero Hermetic Aluminum plate. Ultra-purified nitrogen 
was used as a purge gas at a rate of 50 mL/min. We collected the data using Pyris software 
(PerkinElmer) and analyzed the temperature and the amount of heat transferred per unit time. 
2.2.7 Filaments and 3D Printing 
We used the prepared filaments to print tablets through a fused deposition modeling (FDM) 
3D printer called the Original Prusa i3 MK3S kit (PRUSA RESEARCH S.R.O. ,Prague, Czech 
Republic). The tablet core was made using F1(30% (w/w) Ketoprofen, 50% (w/w) HPMC K4M 
and 20% (w/w) HPMC- AS HG) and the outside shell was made up of F2(30% (w/w) 
Ketoprofen, 50% (w/w) HPMC K4M and 10% (w/w) HPMC- AS HG 10% HPC LF). We then 
imported the design into Ultimaker CURA software (version 3.4.1; Ultimaker, Geldermalsen, 
The Netherlands) to prepare it for printing. 
The printing setting were as follows: printing temperature: 220℃; build plate temperature: 45℃; 
layer height: 0.06mm; wall thickness: 0.8mm; wall line count: 2; top/bottom thickness: 0.6mm; 
top/bottom layers: 10; horizontal expansion: 0mm; print speed: 60mm/s; build plate adhesion 
type: brim. 






2.2.8 Scanning Electron Microscopy (SEM) 
The cross sections and surfaces of the shell and core of the printed tablet were analyzed 
using a JSM-7200 FLV Field-Emission Scanning Electron Microscope (SEM) (JEOL, Peabody, 
MA, U.S.). All samples are covered by a gold layer by a gold sputtering system for 30 s at ~ 70 
mTorr pressure for visualization. Pictures were then taken by a Canon 60D camera (Canon, 
Tokyo, Japan). SEM is critical to our understanding of the internal structure of microscopic 
drugs, so we can also get more information about the potential release mechanism of drugs 
( Siepmann and Göpferich, 2001). 
2.2.9 Tablet Morphology Test 
In this study, VWR® Digital Calipers (VWR®, PA, U.S.) were used to get the precise 




standard tablet hardness tester (VK200; Agilent Technologies, Santa Clara, CA, USA) was used 
to determine the hardness of tablets, and each group was also be measured five times. 
2.2.10 In Vitro Drug Release Study 
A drug dissolution profile was obtained by the United States Pharmacopoeia (USP)-II 
Dissolution Apparatus (Hanson SR8-plusTM; Hansen Research, Chatsworth, Calif., USA) for 
3D Printing tablets. The dissolution test was performed according to the United States 
Pharmacopoeia standards using a Phosphate Buffer (pH 6.8). Each experiment was performed in 
triplicate using 900 mL of the dissolution medium for 24 hours at 37℃ with the paddle speed set 
to 50 rpm peddle speed and samples were taken at 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 12, 24 hours and 
analyzed. The amount of Ketoprofen released was determined by HPLC (Waters Corp., Milford, 
MA, USA) at 246nm using methanol: water as 7:3 as the moving phase and the sample analysis 
was performed using Empower software (version 2, Waters Corp.). 
2.2.11 Dissolution Mathematical Model Study 
An OriginPro 2019 64bit (OriginLab, Northampton, MA, U.S.) was used to analyze and 
create the dissolution curve in this study. The previous data from the in vitro drug release was 
imported to OriginPro 2019 64bit and choose the non-linear fitting and drawing and analyzing its 
relative curve carried out. In this experiment, we investigated the relationship between solubility 
and common mathematical release models of dissolution: zero-order kinetic release model, first-




compatibility with various models, the most suitable mathematical dissolution model for 
ketoprofen-3D Printing tablets was selected to provide more accurate prediction of dissolution 
for future production. Correlation coefficient(R2 ⁠) was an important parameter in this study to 

















3. Results and Discussion 
3.1   Thermal Analysis 
From the TGA result (Fig.5), ketoprofen was been observed start to degrade after 290℃ and 
other polymers start degrade around 350℃, so that also means the samples would stay stable 
during the HME 150℃ and 3D printing 220℃. 
    The DSC curves for homogeneous F1 and F2 mixtures without HME process are for the 
Core and Shell curves respectively in Figure 6 below. Their DSC curve peaked at about 93℃. 
The curves of F1 and F2 after the HME process are the core and shell print shown in the Figure6. 
It can be clearly seen that after the heating process, there is no peak in F1 and F2, which shows 
that ketoprofen successfully formed homogeneous solid dispersion and achieved the amorphous 





Figure 5. TGA thermogram for ketoprofen, HPMC- K4M, HPMCAS-HG and HPC-LF 
 
Figure 6. DSC thermogram for F1 and F2 homogeneous mixture and the printed core and shell grinded powder 
 
KlucelTM HPC LF can be an immediate release- tablet binder, and AquaSolveTM HPMC-AS 
HG can be a controlled release tablet binder. So when we add AquaSolveTM HPMC-AS HG into 




effects. The different formulation design, combined with the difference between internal and 
external densities, can make the drugs in the shell release at a different rate, reaching the 
minimum effective concentration more quickly. Alongside that, a modified core can help to 
maintain a high blood concentration longer. This cascade makes the duration of action of the 
drug longer and maintain blood levels within the therapeutic window for a longer period of time. 
Two formulations of ketoprofen- loaded filaments were successfully produced through the 
HME process. Compared to conventional methods, HME produces filaments which cause the 
API and polymer to form an amorphous condition in the molten state, and it squeezes more air 
out so that they can be intimately mixed. The lower porosity facilitates the of controlled release 
drug, which provides better control of its release curve. HME's extrusion process increases the 
hardness of the filaments and reduces the elastic deformation, which can better meet the 
requirements of 3D Printing. 
 
3.2 Filament Texture Analysis 
During 3D Printing, the filament is wound by a rotatable axle and fed automatically at a 
constant speed through a rigid feeding gear. Because of this, the filaments must have certain 
properties to work in the feeding system. If the filaments are not hard enough or too brittle or the 
viscosity is too low, they will be easily be broken during the feeding process and the printing 




than pharmaceutical area, so we can compare the filaments we made with standard PLA to judge 
whether they are suitable for printing. Viscosity; hardness and brittleness are the most important 
parameters to look at when evaluating the compliance of filaments. The ability to deform a 
material when it is stressed is called ductility. The properties of the material itself that are hard 
and difficult to bend are defined as stiffness, which is when the ductility is low (Rösler et al., 
2007). The stiffness is the key to determining whether the filaments can be successfully fed into 
the 3D Printer's feeder, because the filaments are easily broken during this process. According to 
physics, the brittleness should be calculated like this formula: 
Stiffness= F/ δ 
Here, the applied force is F, and deformation is δ. In this study, we think that the breaking 
force is applied force, and the breaking distance represents deformation. In 3-point bending test, 
the breaking force means the magnitude of the force let filaments break. The breaking distance is 
the distance from the filaments start deformation till fracture. Then using these two parameters 
we can calculate the stiffness of the filaments. In this study, each group of filaments was tested 
and printed ten times. Successful printing for more than six times would be defined as adequate 
properties for 3D Printing. According to the previous study, we already chose the filaments good 
for printing in this study. As such, both F1 and F2 show good mechanical properties and have 
been printed successfully ten times each. 













PLA 1189±12.62 3.75±0.21 10825.054±366.197 317.6±14.71 adequate 
F1 628.78±25.49 8.57±0.96 6933.691±974.492 73.36±28.01 adequate 
F2 431.5±9.44 6.8±0.45 7006.152±434.166 63.46±11.23 adequate 
 
Compared with PLA, F1 and F2 require a relatively larger breaking force, and the breaking 
distance and stiffness are relatively smaller. This is because F1 and F2 are relatively soft, and the 
ductility is not easy to be broken. F1's breaking force and breaking distance are larger than F2 
which has added extra HPC LF. It can also be concluded that HPC LF will soften the properties 
of the filaments, and HPMC AS-HG has higher stiffness than HPC LF. So HPC LF can only be 
added in a small amount to moderate the drug release. If there is too much, the filament cannot 
meet the requirements of 3D Printing. 
 
3.3 Tablets Morphology Analysis 
As shown in Figure 6, 3D Printing drug can maintain the stability of the print to produce 
tablets with specifications. Figure 7 shows the shells from 20% to 30% 40% from left to right. It 




lower density of the tablet is less precise. Figure 7b is 40% 50% 60% core from left to right, 
because the smaller the outer surface is smoother and less rough, but compared to Figure 7a, the 
difference in density can be clearly compared. Figure 7c shows a printed shell on the left and a 









The SEM pictures of core and shell cross-section of 3D printed tablets show that the tablets are 
smooth and have excellent performance. Figure 8 also proved the difference of the 3D printing 
densities microscopically. For the outside shell it looked really porous and loose and for the 
inside core was much tighter. It can also be seen the layer by layer printing style form the bottom 
left one (Fig 8).  
It can be seen from Figure 8 that 3D printing has demonstrated the advantages of stable 









The geometric characteristics for 3D printed tablets data (Table 4) shows pretty consistent, it 
means the printed tablets had really good stability at size. It can be seen from the data (Table 4) 
that due to the special structure of the shell core of the tablet, its hardness mainly depends on the 
density of the shell and is independent of the core, hardness would increase with the density 
increase. It can be seen from Table 4 that 3D printing has demonstrated the advantages of stable 
quality of printed tablets in the pharmaceutical area, which laid the foundation for research 
consistency.  
 
Table 4. Geometric characteristics of the 3D printed tablets 
Tablets Diameter(mm) Height(mm) Weight(mg) Hardness(kp) 
20%Shell 
40%Core 
10.04±0.17 5.07±0.08 337±24 14.4±0.1 
20%Shell 
50%Core 
10.14±0.32 5.05±0.09 339±30 14.4±0.1 
20%Shell 
60%Core 
10.08±0.28 5.02±0.05 347±12 14.4±0.1 
30%Shell 
40%Core 






9.98±0.23 5.02±0.06 340±12 15.1±0.2 
30%Shell 
60%Core 
10.17±0.29 5.17±0.08 351±10 15.1±0.2 
40%Shell 
40%Core 
10.01±0.09 5.04±0.19 343±18 15.3±0.3 
40%Shell 
50%Core 
10.05±0.13 5.12±0.25 357±21 15.4±0.2 
40%Shell 
60%Core 
10.05±0.17 5.15±0.03 347±19 15.4±0.2 
 
3.4 In vitro drug release study 
3D printed tablets of different densities were evaluated by their drug release rates curve. The 
3D printed drugs all show good properties in controlled release rates because they have higher 
hardness, toughness and stiffness. It can be seen from Figure 9 that the release rate of a 3D 
printed drug is significantly slower as the density of the shell and core increases. This shows that 
we have successfully used a density gradient difference to produce 3D printed tablets that control 




40% core, which makes the dissolution profile optimal. In the previous research, due to the 
special nature of 3D printing, the printed structure is very hard and compact, so it is 
recommended to try not to let the core have too high density under the condition of model 
design, which is not conducive to dissolution.  
It is also clear from the dissolution curve that the density is one of the important factors 
when determining the dissolution rate of 3D Printing tablets. 3D printing requires only the 
change of the parameters in the software to make the operation more simple, fast and intuitive, 







Figure 9. In vitro drug release profiles of tablets T1-T9, 100mg ketoprofen released from the HPMC and HPC 
matrix 
 
3.5 Dissolution Kinetic Studies 
The in vitro dissolution rate of a drug is an important parameter for determining formulation. 
When the dissolution rate of a certain dosage is expressed by a special mathematical function, it 
is easier to make a quantitative analysis of the dissolution prediction. Here a model of kinetics is 
used, where the drug release (Q(t)) over time is a function of time (t). To better analyze the 
dissolution of the drug, the following function is used here for analysis (Costa and Lobo, 2003). 
3.5.1 Zero-order Kinetic Release Model 
The formula here is: Q(t)=Q0+K0t. Where Q(t) is the release amount of the drug at time t, K0 
is the zero-order dissolution rate and it is a constant value, and M0 is the initial amount of the 
drug in the solution at the initial state, that is, when t=0 (Vareles et al., 1995). 
3.5.2 First-order Kinetic Release Model 
This model uses the formula, lnQ(t)=lnQ0+K1*t. It’s equal to Q(t)= Q0*(1-e
- K1t), where Q(t) 
is the release amount of the drug at time t, K1 is the first-order dissolution rate and. In this 
circumstances, the percentage of drugs eliminated per unit time in the body remains constant 




3.5.3 Higuchi Model  
This formula is: Q(t)= Q0 + KH*t
1/2. Where Q(t) is the release amount of the drug at time t, KH is 
the drug release rate of Higuchi model and this model is the most common model to describe the 
controlled release drug (Gohel et al., 2000; Petropoulos et al., 2012). 
3.5.4 Ritger - Peppas Model 
The Ritger – Peppas model follows the formula, Q(t) /Q(∞) = ktn. Where Q(t) is the release 
amount of the drug at time t, Q is the release amount of drug at time ∞, 
K and n are coefficients (Ritger and Peppas ., 1987). 
 3.5.5 Analysis of the Drug Using Mathematical Models 
In this research, the parameters of the relevant fitting equations and other calculations can be 
easily calculated by using OriginPro 2019 64bit for the different kinetic release models, zero-
order kinetic release model, first-order kinetic release model, Higuchi model and Ritger -Peppas 
model. OriginPro 2019 64bit software can perform a variety of complex data simulation and 
numerical analysis and drawing operations. Since the original software directly obtains an 
intuitive release curve from the initial data, it can directly observe the data with large dispersion 
and better eliminate the experimental error. 
OriginPro 2019 64bit was used for data linear and nonlinear fitting, and input of the function 




release model(b), Higuchi model (c), Ritger - Peppas model(d) and Peppas- Sahlin model, which 
were used in OriginPro 2019 64bit for the linear and nonlinear curve fitting. Studying these can 
also help us to understand the release of drugs more closely. The release of the drug can be 
divided into Fickian and non-Fickian diffusion. When the drug only has Fickian diffusion, the 
release rate of the drug is independent of the concentration of the drug, and the diffusion 
concentration is only time-dependent with distance. It can be seen from the figure that the first-
order kinetic release model; Ritger-Peppas model fits the curve better than the other 3 models 
(Dash et al., 2010; Costa and Lobo, 2001).  
When considering the results of Ritger-Peppas equation, it can be seen that the fitting error 
at the last moment of cumulative drug release is large, but this can also be explained by the fact 
that the standard deviation of the raw data at the last moment is inherently large. The R2 of the 
Ritger-Peppas equation also shows a good fit. When n ≤ 0.45, it means that there is only Fickian 
diffusion (drug diffusion); when n ≥ 0.89, there is only Case Ⅱ transport (skeletal erosion) and 
when 0.45＜n＜0.89, the drug release mechanism called non-Fick diffusion(anomalous 
transport). So n is the most important parameter in this equation and we printed 9 groups at 
different densities. The fitting results of the tablets all conformed to 0.45<n<0.89, which 
indicates that the dissolution process of this drug has both Fickian diffusion and Case Ⅱ 





In order to better judge which diffusion dominates in the Ketoprofen-based 3D Printing 
tablets, the correction formula of the Ritger-Peppas formula, Peppas-Sahlin model is introduced 
here for further calculation. Q(t) /Q(∞) = k1t
n1 +k2t2
n1, which involves the analysis of several 
variables. The model considers both Fickian diffusion (the first term of the equation) and the 
Case Ⅱ relaxation (the second term of the equation) contribution. If the release of the drug only 
has a Fickian diffusion and the Case Ⅱ relaxation can be completely ignored, the n1 in the 
formula is equal to the n in the Rigter- Peppas formula. Therefore, the difference between n and 
n1 also proves that the release mechanism of the drug is the result of Fickian diffusion and Case 
Ⅱ relaxation coupling. The percentage of drug F released by Fickian diffusion can be calculated 
by the following formula: F=1/(1+k2/k1*t^n1). 
The ratio of Case Ⅱ relaxation R to F can be calculated by the following formula (Peppas and 
Sahlim, 1989; Unagolla and Jayasuriya, 2017): R/F= k2/k1*t^n1. 
Table 5. Dissolution kinetic parameters of 3D printing tablets 
  Zero-order First-order Ritger- Peppas Higuchi Peppas-sahlin 
 K0 R
2 K1 R
2 n R2 KH R
2 K1 K2 N1 R2 
T1 4.22 0.83 0.31 1.00 0.47 0.94 23.23 0.94 0.19 0.07 0.85 1.00 
T2 4.54 0.87 0.29 0.99 0.52 0.97 23.97 0.97 0.18 0.05 0.72 1.00 




T4 5.38 0.71 0.26 0.96 0.59 0.96 22.79 0.98 0.12 0.05 0.67 1.00 
T5 10.30 0.87 0.51 0.98 0.66 0.98 25.24 1.00 0.11 0.02 0.67 1.00 
T6 4.69 0.81 0.32 0.95 0.54 0.98 21.30 0.99 0.13 0.02 0.59 1.00 
T7 4.91 0.87 0.19 0.94 0.50 0.99 20.03 0.99 0.12 0.06 0.53 1.00 
T8 5.68 0.78 0.50 0.95 0.59 0.94 21.39 0.97 0.10 0.04 0.52 0.99 
T9 5.69 0.78 0.49 0.95 0.58 0.94 21.42 0.97 0.09 0.04 0.52 0.99 
 
Because the degradation of drugs is a very complex process as they are affected by not only 
physical factors but also chemical factors. Any mathematical modeling method must consider 
these processes. Although the Higuchi model is the most frequently used model in controlled 
release drug mathematical model fitting, researchers have pointed out that the classical equation 
using the Higuchi model is premised and more suitable for ideal conditions. The release of the 
drug needs to meet the following conditions (Siepmann & Göpferich, 2001; Zhang et al., 2017):  
i. The initial drug concentration should be much higher than the solubility of the 
drug. 
ii. Drug spread is one-dimensional. 




iv. The swelling or dissolution of the iv polymer carrier is negligible. 
   Table 5 shows the different mathematical models fitting results, and after compared with the 
correction coefficient (R2) we can see the Ritger –peppas , higuchi and peppas –sahlin fits the 
drug release more than others. And in all of these 3 model, Peppas-sahlin fits best. Because 
Peppas- sahlin is the correction formula of the Ritger-Peppas formula, so we will also get the 
diffusion method from it. We can use this equation to accurately predict the dissolution and 
release rate of the drug in future, which is of great significance for production. 
Based on these prerequisites, the Higuchi model is not suitable for in vitro release of 3D 
printing in this study. Since the diffusion of the 3D printed tablet is not one-dimensional but 
three-dimensional, the initial drug concentration is not much higher than the solubility of the 
drug, and the swell happened during HPMCAS-HG skeleton erosion. Though Higuchi model fits 
good in here, it won’t be applicable to describe this release profile. 
Table 6. R/F parameters for T1-T9 
 T1 T2 T3 T4 T5 T6 T7 T8 T9 





The table shows R/F of all 9 group tablets are greater than 1, so Case Ⅱ relaxation dominates the 
dissolution part compared to Fickian diffusion. It can also be concluded that as the density 



















In this study we successfully produced ketoprofen-loaded filaments and printed them into 
designed tablets. At the same time, we successfully used the single-punch method to compress 
the tablets and performed a comparison of the in vitro dissolution experiments. Experiments have 
shown that the same material has significantly improved the dissolution rate after HME and 3D 
Printing process, and the therapeutic window of the drug is larger and better. We also confirmed 
that the printing density has a great influence on the dissolution rate of 3D printed tablets by the 
dissolution of 3D printed tablets of different density gradients. When the density is greater, the 
dissolution is slower; and when the density is lower, and the dissolution can be faster in the 
body. The effects of different printing densities on a drug’s rate of release were successfully 
summarized by using the mathematical model, which provided data for the rational prediction of 
drug’s rate of release in the future. 
This research successfully combined 3D printing and HME to produced controlled release 
tablets with different densities. This research provides a foundation for the development of 
controlled release tablets using combined 3D printing and HME technology thus expanding the 
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